ClinicalTrials.gg
TerminatedNCT04385849Updated Sep 5, 2024Results posted

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

A Phase 1 interventional study of N-803 and Saline in COVID-19, sponsored by ImmunityBio, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by ImmunityBio, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
1,228th of 1,321
1 · median 91
Started
2020
with 817 others
Phase 1
178 of 1,859
10 open now
Registered
299th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 1,228th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 178 in phase 1, and was the 299th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1b, randomized, blinded, placebo-controlled study in adult subjects with COVID-19. This clinical trial is designed to assess the safety and immunostimulatory activity of N-803.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old.
  2. Able to understand and provide a signed that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
  3. Has laboratory-confirmed positive novel coronavirus (SARS-CoV-2) test, as determined by polymerase chain reaction (PCR), or other commercial or public health assay in any specimen \< 72 hours prior to enrollment, or meets the criteria to guide the evaluation and testing of patients under investigation (PUI) for COVID-19 (https://emergency.cdc.gov/han/2020/HAN00428.asp).
  4. Has a confirmed NEW score of 0-5.
  5. Has at least one of the following high-risk factors associated with a higher risk of COVID-19 progression:

    1. Age ≥ 60 years.
    2. Hypertension currently managed by at least 1 antihypertensive medication.
    3. Type 1 or 2 diabetes.
    4. (COPD) diagnosed per medical history.
  6. Adequate respiratory and heart function, evidenced by the following laboratory results:

    1. Respiratory rate (RR) \< 20 breaths per minute (bpm).
    2. Heart rate (HR) \< 90 beats per minute (bpm).
    3. Arterial oxygen saturation (SaO2) > 93% on room air.
  7. Agrees to the collection of nasopharyngeal (NP) swabs and venous blood per protocol.
  8. Ability to participate in required study visits and participate in adequate follow-up, as required by this protocol.
  9. Agreement to practice effective for female subjects of and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception while on study and for at least 1 month after the last dose of N-803. Non-sterile male subjects must agree to use a condom while on study and for up to 1 month after the last dose of N-803. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), oral contraceptives, and abstinence.

Exclusion criteria

Exclusion Criteria:

  1. Shortness of breath or hypoxia defined by a ratio of partial pressure of arterial oxygen to the percentage of inspired oxygen (PaO2/FiO2) ≤ 300 mmHg or signs of serious lower airway disease.
  2. Signs or symptoms of acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS)/shock, or cardiac failure; or need for supplemental oxygen.
  3. Inflammatory markers (C-reactive protein [CRP], lactate dehydrogenase [LDH], d-dimer, ferritin, and IL-6) > 1.5 × (ULN).
  4. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  5. Pregnant and nursing women. A negative serum or urine pregnancy test during screening prior to the first dose must be documented before N-803 is administered to a female subject of .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Experimental Arm

    N-803 Recombinant human super agonist interleukin-15 (IL-15) complex

    Biological: N-803

  • Placebo comparator
    Placebo Arm

    Sterile saline solution

    Other: Saline

Interventions

  • BiologicalN-803

    Recombinant human super agonist interleukin-15 (IL-15) complex

  • OtherSaline

    Sterile saline solution

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0

    Time frame: 3 days

07

Results

Posted Sep 5, 2024
Limitations and caveats
The study is terminated early due to low enrollment. Effect of the study drug on efficacy was not analyzed.

Participant flow

Participant flow — Overall Study
MilestoneExperimental ArmPlacebo Arm
Started10
Completed00
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryNumber of Participants With Adverse Events

AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0

Time frame:
3 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsExperimental ArmPlacebo Arm
Number of Participants With Adverse Events10

Adverse events

Collected over The planned follow up time was 29 days post dose, but the one participant enrolled was lost to follow up 3 days post dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm0/1 (0%)0/1 (0%)0/1 (0%)
Placebo Arm———

Baseline characteristics

No subjects were enrolled in the Placebo arm.

Age, Continuous
Age, Continuous(years)Experimental ArmPlacebo ArmTotal
Mean70 ± 0—70 ± 0
Sex: Female, Male
Sex: Female, Male(Participants)Experimental ArmPlacebo ArmTotal
Female0—0
Male1—1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental ArmPlacebo ArmTotal
Hispanic or Latino1—1
Not Hispanic or Latino0—0
Unknown or Not Reported0—0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental ArmPlacebo ArmTotal
American Indian or Alaska Native0—0
Asian0—0
Native Hawaiian or Other Pacific Islander0—0
Black or African American0—0
White1—1
More than one race0—0
Unknown or Not Reported0—0
08

Study locations

1 site
  • St. Francis
    Lynwood, California 90262, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Jul 2020, 0 months.

Results were first posted in Sep 2024, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2020
First posted
May 13, 2020
StartActual
Jul 22, 2020
Primary completionActual
Jul 25, 2020
CompletionActual
Jul 25, 2020
Results first posted
Sep 5, 2024
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04385849
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
May 13, 2020
Start date
Jul 22, 2020
Primary completion
Jul 25, 2020
Completion
Jul 25, 2020
Results posted
Sep 5, 2024
Last update
Sep 5, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion